Araştırma Makalesi

EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS

Cilt: 20 Sayı: 1 25 Şubat 2019
PDF İndir
EN TR

EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS

Öz

The present study aimed to compare the choroidal thickness of the patients diagnosed with type 1 diabetes mellitus (DM) with no sign of diabetic retinopathty (DR) in the endocrinology policlinic and with the choroidal thickness of healthy subjects.

MATERIAL AND METHODS: The patients were screened at horizontal level using spectral domain optical coherence tomography device (Nidek SLO/Spectral OCT (RS 3000)). Choroidal thickness was measured from a total of seven points in the subfoveal area horizontally at 600μm intervals to a distance of 1200 μm in the nasal and temporal quadrants. The patients with type 1 diabetes were assigned to Group 1 and the control subjects were assigned to Group 2. Patients with corneal opacity, cataract, retinal disease, family history of glaucoma or history of ocular surgery, uncontrolled hypertension, and cardiovascular disorders were excluded.

RESULTS: The study comprised 20 eyes of 10 Type 1 DM patients without DR and 16 eyes of eight control subjects. No significant difference was determined between the groups in terms of age, gender, spherical equivalent, best corrected visual acuity, intraocular pressure and axial length. In Group 1, subfoveal choroidal thickness was 311.6μm in the right eye and 348.7μm in the left eye. In Group 2, subfoveal choroidal thickness was 377.1μm in the right eye and 368.9μm in the left eye. The choroidal thickness has become thinner in the nasal vs. temporal quadrant both in Group 1 and Group 2 (p=0.039). Comparing the choroidal thickness between the groups, it was found to be higher in Group 2, but the difference was not statistically significant (p=0.214).

CONCLUSIONS: Type 1 diabetes mellitus has more aggressive impacts on the eye than those of type 2 diabetes, but it appears to have lower impact on the choroid, which is rich in vascular structure. Although choroidal thickness was determined to be decreased in type 1 diabetes mellitus, the results were not statistically significant. We assume that the results might change in case the data is augmented with larger number of type 1 diabetes mellitus patients. Moreover, manual measurement of choroidal thickness using SD-OCT may give different results.

Anahtar Kelimeler

Kaynakça

  1. 1.Norris A.W, Wolfsdorf J.I. Diabetes Mellitus. In: Brook G.D.C,Clayton P.E, Brown RS, Savage M.O (eds). Clinical Pediatric Endocrinology. 5 edition. Massachusetts (USA): Blackwell Publishing Ltd; 2005:436-91. 18
  2. 2. Marçal AC, Leonelli M, Fiamoncini J, et al. Diet-inducedobesity impairs AKT signaling in the retina and causes retinal degeneration. Cell Biochem Funct. 2013;31:65-74.
  3. 3. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105:998–1003.
  4. 4. Koca C, Altan N, Dinçel AS, Kosova F, Şahin D, Arslan M. Tip 1ve Tip 2 Diyabetik Hasta Serumlarında Oksidatif Stres ve Leptin Düzeylerinin incelenmesi. Türk Klinik Biyokimya Derg 2008; 6(3): 99-107.
  5. 5. Hidayat AA, Fine BS. Diabetic choroidopathy. Lightand electron microscopic observations of seven cases. Ophthalmology. 1985; 92:512–522.
  6. 6.Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillarisdegeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol. 1998; 116:589–597.
  7. 7.Reiner A, Del Mar N, Zagvazdin Y, Li C, Fitzgerald ME. Agerelated impairment in choroidal blood flow compensation for arterial blood pressure fluctuation in pigeons. Invest Ophthalmol Vis Sci 2011; 52: 7238–47.
  8. 8. Nagaoka T, Kitaya N, Sugawara R, et al. Alteration of cho¬roidal circulation in the foveal region in patients with type 2 diabetes. Br J Ophthalmol. 2004;88:1060-63

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Leyla Eryiğit Eroğul Bu kişi benim

Yayımlanma Tarihi

25 Şubat 2019

Gönderilme Tarihi

15 Ocak 2018

Kabul Tarihi

28 Mayıs 2018

Yayımlandığı Sayı

Yıl 2019 Cilt: 20 Sayı: 1

Kaynak Göster

APA
Eroğul, Ö., & Eryiğit Eroğul, L. (2019). EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS. Kocatepe Tıp Dergisi, 20(1), 14-18. https://doi.org/10.18229/kocatepetip.532105
AMA
1.Eroğul Ö, Eryiğit Eroğul L. EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS. KTD. 2019;20(1):14-18. doi:10.18229/kocatepetip.532105
Chicago
Eroğul, Özgür, ve Leyla Eryiğit Eroğul. 2019. “EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS”. Kocatepe Tıp Dergisi 20 (1): 14-18. https://doi.org/10.18229/kocatepetip.532105.
EndNote
Eroğul Ö, Eryiğit Eroğul L (01 Şubat 2019) EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS. Kocatepe Tıp Dergisi 20 1 14–18.
IEEE
[1]Ö. Eroğul ve L. Eryiğit Eroğul, “EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS”, KTD, c. 20, sy 1, ss. 14–18, Şub. 2019, doi: 10.18229/kocatepetip.532105.
ISNAD
Eroğul, Özgür - Eryiğit Eroğul, Leyla. “EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS”. Kocatepe Tıp Dergisi 20/1 (01 Şubat 2019): 14-18. https://doi.org/10.18229/kocatepetip.532105.
JAMA
1.Eroğul Ö, Eryiğit Eroğul L. EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS. KTD. 2019;20:14–18.
MLA
Eroğul, Özgür, ve Leyla Eryiğit Eroğul. “EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS”. Kocatepe Tıp Dergisi, c. 20, sy 1, Şubat 2019, ss. 14-18, doi:10.18229/kocatepetip.532105.
Vancouver
1.Özgür Eroğul, Leyla Eryiğit Eroğul. EVALUATION OF SUBFOVEAL CHOROIDAL THICKNESS USING SPECTRALIS OCT IN THE PATIENTS WITH TYPE 1 DIABETES MELLITUS. KTD. 01 Şubat 2019;20(1):14-8. doi:10.18229/kocatepetip.532105

88x31.png
Bu Dergi Creative Commons Atıf-GayriTicari-AynıLisanslaPaylaş 4.0 Uluslararası Lisansı ile lisanslanmıştır.